A complementary new drug for PNH

被引：7
|
作者：
Brodsky, Robert A. [1 ]
机构：
[1] Johns Hopkins Univ, Baltimore, MD 21218 USA
来源：
BLOOD | 2020年 / 135卷 / 12期
关键词：
D O I：
10.1182/blood.2020004959
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
In this issue of Blood, Roth et al show in a phase 1/2 trial that crovalimab, a subcutaneously administered monoclonal antibody that targets C5, is safe and effective in treating paroxysmal nocturnal hemoglobinuria (PNH).(1) Crovalimab targets a C5 epitope that is different from the IV C5 inhibitors, eculizumab and ravulizumab. Crovalimab is administered subcutaneously every 4 weeks.
引用
收藏
页码：884 / 885
页数：3
相关论文
共 50 条
12345